CRL — Charles River Laboratories Inte

Is CRL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

Charles River Laboratories Inte (CRL) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $290.00. The rating moved from Neutral to Overbought on August 6, 2026.

See all overbought Healthcare stocks →

AI analysis

Charles River Laboratories Inte is well-positioned to capture ongoing demand from biologics, GLP-1 and AI-enabled protein-design workflows that favor outsourced lab and CDMO capacity. The firm’s diversified services, regulatory know-how and scale support steady revenue visibility and margin improvement opportunities. Near-term catalysts include continued biotech R&D activity, potential sector M&A tailwinds, and adoption of automated/AI-enabled lab workflows that boost throughput. Key vulnerabilities include the possibility of R&D budget retrenchment, competitive pricing pressure, and operational or regulatory setbacks that could materially affect timing of revenues and margins. Given the current market tone, the outlook favors gradual upside while remaining sensitive to macro and execution risks.

Key factors

  • Direct exposure to CRO/CDMO demand from accelerating biologics, protein-design and GLP-1 related R&D that supports sustained service volumes and pricing power
  • Broad service offering across preclinical, discovery, safety assessment and lab services creates diversified revenue streams and recurring client relationships
  • Industry structural tailwinds from AI-driven protein design and increased outsourcing of wet-lab and synthesis work to independent providers
  • Elevated biotech/pharma M&A and high buyer multiples that can support strategic deal activity and premium valuations for specialist service providers
  • Resilient near-term market backdrop with steady order flow and limited macro headline risk in the immediate trading window
  • Operational scale and regulatory expertise that create barriers to entry and competitive advantage versus smaller labs

Risks

  • Pharma/biotech R&D budget cuts or reprioritization that reduce outsourcing demand or delay large programs
  • Pricing pressure and competition from other CROs, CDMOs and vertically integrated pharma lab networks
  • Regulatory or quality-control incidents that could disrupt operations, delay studies or damage reputation
  • Macroeconomic and interest-rate driven valuation compression that could weigh on multiples despite solid fundamentals
  • Currency exposure and global footprint risks (supply chain, labor availability) that could compress margins
  • Customer concentration for large accounts and potential timing volatility in milestone-driven revenue

See today's live rating, score and targets

Members see the live hourly rating for CRL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.